Hyperion Therapeutics Major Shareholder Highland Management Partners V Sells 34,573 Shares (HPTX)
Hyperion Therapeutics (NASDAQ:HPTX) major shareholder Highland Management Partners V unloaded 34,573 shares of Hyperion Therapeutics stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $26.56, for a total value of $918,258.88. The sale was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
A number of research firms have recently commented on HPTX. Analysts at Needham & Company reiterated a “buy” rating on shares of Hyperion Therapeutics (NASDAQ:HPTX) in a research note to investors on Thursday, August 15th. They now have a $35.00 price target on the stock, up previously from $25.00. Separately, analysts at Zacks downgraded shares of Hyperion Therapeutics (NASDAQ:HPTX) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, August 7th. They now have a $28.20 price target on the stock. Finally, analysts at Zacks upgraded shares of Hyperion Therapeutics (NASDAQ:HPTX) from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, July 9th. They now have a $24.30 price target on the stock.
One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $31.55.
Shares of Hyperion Therapeutics (NASDAQ:HPTX) traded down 1.40% on Thursday, hitting $25.98. 34,844 shares of the company’s stock traded hands. Hyperion Therapeutics has a one year low of $10.00 and a one year high of $28.34. The stock’s 50-day moving average is $24.97 and its 200-day moving average is $23.05. The company has a market cap of $521.9 million and a P/E ratio of 161.66.
Hyperion Therapeutics (NASDAQ:HPTX) last released its earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.05. The company had revenue of $7.30 million for the quarter, compared to the consensus estimate of $2.17 million. Analysts expect that Hyperion Therapeutics will post $0.67 EPS for the current fiscal year.
Hyperion Therapeutics, Inc (NASDAQ:HPTX)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.